This sector ’remains unfavored’ by investors despite strong fundamentals says UBS

UBS indicates that the U.S. medical supplies and devices (MedTech) sector remains unfavored by investors, experiencing significant outflows and underperformance since Q2 2025 despite strong underlying fundamentals and solid results. The bank views the current investor rotation out of MedTech as a buying opportunity, anticipating healthy procedure volume trends driven by ongoing innovation in Q3, even amidst tariff uncertainty and Medicaid-related headwinds. UBS believes investor concerns regarding growth sustainability, even in high-quality names, are overstated looking towards 2026.

Analysis

UBS highlights the U.S. medical supplies and devices (MedTech) sector as "unfavored" by investors, experiencing significant outflows and underperformance since Q2 2025 despite strong underlying fundamentals. The bank notes that healthcare overall remains at multi-decade lows as a percentage of the S&P, with MedTech particularly lagging. Despite a "solid 2Q25 across the board," generalist investors are exiting, preventing a sustainable bid for the sector.

UBS views the current investor rotation out of MedTech as a "buying opportunity," maintaining a bullish stance on group fundamentals. The bank anticipates healthy procedure volume trends in Q3, driven by ongoing innovation, which should support future performance. While acknowledging tariff uncertainty and Medicaid-related headwinds, UBS believes these factors are not sufficient to negate the sector's long-term potential.

Post-Q2, sentiment within MedTech has "retrenched significantly," leading even high-quality stocks like BSX and ISRG to roll over as generalists take profits. UBS, however, believes that increasing investor concerns regarding the sustainability of growth for these top-tier names are "overstated" when looking ahead to 2026, indicating a potential disconnect between current market sentiment and fundamental value.

Key Decisions for Investors

• Investors should consider the current MedTech sector underperformance, particularly in high-quality names like BSX and ISRG, as a potential buying opportunity given UBS's bullish fundamental outlook for 2026.
• Monitor Q3 earnings reports for confirmation of healthy procedure volume trends and ongoing innovation, as these are key drivers for a sentiment shift in the sector.
• Evaluate the impact of tariff uncertainty and Medicaid-related headwinds on individual company guidance, while recognizing UBS believes long-term growth concerns for top names are overstated.